IGM Biosciences, Inc. Stock price

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 01/03/2024 GMT 5-day change 1st Jan Change
12.65 USD +0.16% Intraday chart for IGM Biosciences, Inc. -2.24% +52.23%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * 2.36M 186M Sales 2024 * 11.08M 875M Capitalization 739M 58.31B
Net income 2023 * -250M -19.73B Net income 2024 * -245M -19.34B EV / Sales 2023 * 172 x
Net cash position 2023 * 332M 26.21B Net cash position 2024 * 90.28M 7.13B EV / Sales 2024 * 58.5 x
P/E ratio 2023 *
-2.63 x
P/E ratio 2024 *
-3.26 x
Employees 290
Yield 2023 *
-
Yield 2024 *
-
Free-Float 32.6%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.16%
1 week-2.24%
Current month+0.16%
1 month+10.10%
3 months+103.54%
6 months+81.49%
Current year+52.23%
More quotes
1 week
12.51
Extreme 12.51
14.96
1 month
10.75
Extreme 10.75
17.70
Current year
8.14
Extreme 8.135
17.70
1 year
3.81
Extreme 3.81
22.37
3 years
3.81
Extreme 3.81
99.44
5 years
3.81
Extreme 3.81
133.00
10 years
3.81
Extreme 3.81
133.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 31/01/03
Director of Finance/CFO 49 31/12/18
Chief Tech/Sci/R&D Officer - 31/12/20
Members of the board TitleAgeSince
Director/Board Member 55 25/01/21
Director/Board Member 71 30/01/19
Chief Executive Officer 72 31/01/03
More insiders
Date Price Change Volume
01/03/24 12.65 +0.16% 376,202
29/02/24 12.63 -7.74% 184,462
28/02/24 13.69 -3.66% 97,382
27/02/24 14.21 +2.01% 223,903
26/02/24 13.93 +7.65% 194,445

Delayed Quote Nasdaq, March 01, 2024 at 09:00 pm

More quotes
IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The Company has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
12.65 USD
Average target price
20.6 USD
Spread / Average Target
+62.85%
Consensus
  1. Stock
  2. Equities
  3. Stock IGM Biosciences, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW